These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3476764)

  • 61. Low-dose cytarabine therapy in hypoplastic acute leukemia.
    Manoharan A
    N Engl J Med; 1983 Dec; 309(26):1652-3. PubMed ID: 6580525
    [No Abstract]   [Full Text] [Related]  

  • 62. In vitro sensitivity of various human tumors to 1-beta-D-arabinofuranosylcytosine and N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Maehara Y; Kusumoto T; Kusumoto H; Anai H; Sugimachi K
    Chemotherapy; 1989; 35(3):181-6. PubMed ID: 2766858
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Successful treatment of chronic myelomonocytic leukemia (CMMoL) with N4-palmitoyl-1-beta-D-arabinofuranosylcytosine (PLAC)].
    Ozawa M; Iwamoto K; Kitani K; Mizuno T; Kobayashi Y; Horiuchi H; Maruo N; Kondo M; Horiike S; Misawa S
    Rinsho Ketsueki; 1988 Dec; 29(12):2297-301. PubMed ID: 3246714
    [No Abstract]   [Full Text] [Related]  

  • 64. [The effect of N4-behenoyl-1-beta-D-arabinofuranosylcytosine on human erythrocytes].
    Moriguchi T; Kakita T; Nishimura T; Kubo A; Ueda T; Nakamura T; Sasada M; Uchino H
    Rinsho Ketsueki; 1987 Sep; 28(9):1568-75. PubMed ID: 3437519
    [No Abstract]   [Full Text] [Related]  

  • 65. [High-dose cytarabine therapy in acute myeloid leukemia].
    Kawamura M; Ohshima T
    Rinsho Ketsueki; 1986 Aug; 27(8):1468-75. PubMed ID: 3467104
    [No Abstract]   [Full Text] [Related]  

  • 66. Antiviral effect of antileukemic drugs N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) and 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine (cyclo-C) against human cytomegalovirus.
    Nakamura K; Eizuru Y; Kumura K; Minamishima Y
    J Med Virol; 1990 Jun; 31(2):141-7. PubMed ID: 1696958
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cytokinetic study on the effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine on murine leukemic cells L 1210: a comparison with the effects of 1-beta-D-arabinofuranosylcytosine.
    Maruo N; Horiuchi H; Nakabo T; Kondo M; Nakamura T
    Hematol Oncol; 1985; 3(1):39-48. PubMed ID: 2580770
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Influences of aging on clinical pictures of hematological diseases: hypoplastic leukemia in the aged].
    Ohnoshi T; Takahashi I; Ohmoto E; Nakada H; Nishimura M; Nonaka K
    Nihon Ronen Igakkai Zasshi; 1987 Mar; 24(2):128-31. PubMed ID: 3476778
    [No Abstract]   [Full Text] [Related]  

  • 69. [Current chemotherapeutic approaches in acute myeloid leukemia].
    Ohtake S
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():394-8. PubMed ID: 23133989
    [No Abstract]   [Full Text] [Related]  

  • 70. Cytarabine dose for acute myeloid leukemia.
    Mathisen MS
    N Engl J Med; 2011 Jun; 364(22):2167; author reply 2168-9. PubMed ID: 21631341
    [No Abstract]   [Full Text] [Related]  

  • 71. Immunological erythroblastopenia induced by HCO-60 as a solvent of enocitabine (BH-AC).
    Ninomiya H; Hanada T; Nakazawa M; Aoki Y; Shibuya A; Nagasawa T; Abe T
    Nihon Ketsueki Gakkai Zasshi; 1987 Jul; 50(4):777-83. PubMed ID: 3120451
    [No Abstract]   [Full Text] [Related]  

  • 72. Treatment of juvenile chronic myelocytic leukemia with multidrug chemotherapy including aclacinomycin and N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Ishii E; Matsuzaki A; Kato Y; Miyazaki S; Ueda K
    Nihon Ketsueki Gakkai Zasshi; 1986 Sep; 49(6):1297-9. PubMed ID: 3468729
    [No Abstract]   [Full Text] [Related]  

  • 73. Induction therapy and outcome in acute myeloid leukemia.
    Mehta J
    Cancer; 2011 May; 117(10):2236-7; author reply 2237. PubMed ID: 21523737
    [No Abstract]   [Full Text] [Related]  

  • 74. Phase I clinical and pharmacokinetic study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Kimura K; Ohno R; Amaki I; Hattori K; Hirota Y; Hoshino A; Ichimaru M; Ito M; Kimura I; Maekawa T
    Med Oncol Tumor Pharmacother; 1986; 3(1):15-24. PubMed ID: 3702507
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Acute myeloid leukemia. Effects of treatment and prognosis].
    Johnsen HE; Bergmann OJ; Madsen B; Kristensen JS; Brandsborg M; Ellegaard J; Bastrup-Madsen P
    Ugeskr Laeger; 1987 Jun; 149(24):1598-603. PubMed ID: 3474820
    [No Abstract]   [Full Text] [Related]  

  • 76. Phase I clinical and pharmacokinetic study of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine.
    Ohno R; Kimura K; Ota K; Miura Y; Hoshino A; Hattori K; Hirano M; Ito M; Maekawa T; Nakamura T
    Med Oncol Tumor Pharmacother; 1987; 4(2):67-73. PubMed ID: 3669779
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [High dose androgen therapy: an adjuvant means in the aggressive treatment of acute myeloblastic leukemia? 1st results].
    Tanzer J; Desmaret MC; Frocrain C; Alcalay D; Nivet-Perdoux A; Goube de LaForest P
    Nouv Presse Med; 1976 Nov; 5(38):2543. PubMed ID: 1068442
    [No Abstract]   [Full Text] [Related]  

  • 78. Low-dose combination remission induction therapy for acute myeloid leukaemia in elderly patients--a pilot study.
    Manoharan A
    Aust N Z J Med; 1992 Dec; 22(6):710-1. PubMed ID: 1489302
    [No Abstract]   [Full Text] [Related]  

  • 79. Intracellular pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Higashigawa M; Hori H; Ochiai H; Ohkubo T; Kawasaki H; Nobori T; Kamiya H; Sakurai M
    Adv Exp Med Biol; 1989; 253B():341-8. PubMed ID: 2610121
    [No Abstract]   [Full Text] [Related]  

  • 80. Very-low-dose cytarabine for elderly patients.
    Pesce A; Cassuto JP; Bayle J; Raynaud S; Fuzibet JG; Gratecos N; Dujardin P
    Lancet; 1986 Jun; 1(8495):1436. PubMed ID: 2872529
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.